Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer
- Citation:
- JNCI Cancer Spectr vol 4 (3)
- Year:
- 2020
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Program:
- TRP
- Primary Committee:
- Correl Sci NOS
- Sec. Committees:
- Pharmas:
- Eli Lilly and Company, Pfizer, Bristol-Myers Squibb, Sanofi
- Grants:
- U10CA180821, U10CA180882, R01 CA210509-01A1; UG1CA232760, U10CA180888, U10CA180835 (SWOG), U10CA180863, CCSRI 021039 (CCTG), U10CA180868; U24CA196067 (NRG), U24CA196171
- Corr. Author:
- Authors:
- Frank A Sinicrope Qian Shi Fabienne Hermitte Tyler J Zemla Bernhard Mlecnik Al B Benson Sharlene Gill Richard M Goldberg Morton S Kahlenberg Suresh G Nair Anthony F Shields Thomas C Smyrk Jerome Galon Steven R Alberts
- Networks:
- LAPS-IL036, LAPS-MN026, LAPS-OH007, MCRC
- Study
- NCCTG-N0147
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: